Immunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration
- PMID: 27366236
- PMCID: PMC4916519
- DOI: 10.1177/1756285616637046
Immunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration
Abstract
Objectives: The goal of this study was to analyze safety and assess the efficacy of standard plasma exchange (PE) compared with immunoadsorption (IA) alone, or an alternating combination of both in deteriorating myasthenia gravis (MG).
Methods: A total of 72 patients with MG who had received PE procedures for treatment of severe deterioration were retrospectively analyzed. They received either five cycles of PE (1-1.5 plasma volumes), or five cycles of IA in line with plasma separation, or a sequential alternating procedure of one cycle of PE followed by two cycles of IA, which was repeated once or more if needed.
Results: A total of 19 patients received PE, 24 patients IA, and 29 the alternating combination therapy. All groups were equally distributed by sex and mean MG score before treatment. The number of treatment cycles and days on therapy did not differ between the groups. Mean MG scores at discharge were 3.0 (PE), 1.8 (IA) and 1.6 (combination) (p = 0.028 for combination versus PE). Inpatient time was 30.7 days (PE), 22.3 days (IA) and 20.0 days in combination therapy (p < 0.05 for combination versus PE). Side effects such as allergic reactions or hypocoagulability were significantly more frequent in the PE group (37% in PE versus 4% in IA and 3.6% in the alternating combination, p < 0.05).
Conclusion: Semiselective IA in combination with PE, and to a lesser extent IA alone, was associated with a shorter hospital stay and more pronounced reduction of the MG score than PE.
Keywords: immunoadsorption; myasthenia gravis; myasthenic crisis; plasma exchange; therapy.
Conflict of interest statement
Similar articles
-
Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial.EClinicalMedicine. 2019 Nov 14;16:98-106. doi: 10.1016/j.eclinm.2019.10.017. eCollection 2019 Nov. EClinicalMedicine. 2019. PMID: 31832624 Free PMC article.
-
A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.J Clin Apher. 2011 Dec;26(6):347-55. doi: 10.1002/jca.20317. Epub 2011 Nov 17. J Clin Apher. 2011. PMID: 22095647 Clinical Trial.
-
Safety and Tolerability of Plasma Exchange and Immunoadsorption in Neuroinflammatory Diseases.J Clin Med. 2020 Sep 5;9(9):2874. doi: 10.3390/jcm9092874. J Clin Med. 2020. PMID: 32899499 Free PMC article.
-
Immunoadsorption in Guillain-Barré syndrome and myasthenia gravis.Ther Apher. 2000 Jun;4(3):195-7. doi: 10.1046/j.1526-0968.2000.00183.x. Ther Apher. 2000. PMID: 10910018 Review.
-
[Plasmapheresis in patients with myasthenia gravis].Nihon Rinsho. 2008 Jun;66(6):1165-71. Nihon Rinsho. 2008. PMID: 18540364 Review. Japanese.
Cited by
-
Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica.Ther Adv Neurol Disord. 2018 May 28;11:1756286418774973. doi: 10.1177/1756286418774973. eCollection 2018. Ther Adv Neurol Disord. 2018. PMID: 29872456 Free PMC article.
-
Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial.EClinicalMedicine. 2019 Nov 14;16:98-106. doi: 10.1016/j.eclinm.2019.10.017. eCollection 2019 Nov. EClinicalMedicine. 2019. PMID: 31832624 Free PMC article.
-
Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients - A validation study in plasma and cerebrospinal fluid from two Swedish cohorts.Brain Behav Immun Health. 2020 Jul 18;7:100107. doi: 10.1016/j.bbih.2020.100107. eCollection 2020 Aug. Brain Behav Immun Health. 2020. PMID: 34589868 Free PMC article.
-
Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders.Jpn J Ophthalmol. 2018 Jul;62(4):525-530. doi: 10.1007/s10384-018-0602-9. Epub 2018 May 25. Jpn J Ophthalmol. 2018. PMID: 29802557
-
Pattern Recognition of the Multiple Sclerosis Syndrome.Brain Sci. 2017 Oct 24;7(10):138. doi: 10.3390/brainsci7100138. Brain Sci. 2017. PMID: 29064441 Free PMC article. Review.
References
-
- Besinger U., Toyka K., Hömberg M., Heininger K., Hohlfeld R., Fateh-Moghadam A. (1983) Myasthenia gravis: Long term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33: 1316–1321. - PubMed
-
- Clauss A. (1957) Rapid physiological coagulation method in determination of fibronogen. Acta Haematol 17: 237–246. - PubMed
-
- Dalakas M. and Medscape (2011) Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 7: 507–517. - PubMed
-
- Gajdos P., Chevret S., Clair B., Tranchant C., Chastang C. (1997) Clinical trial of plasma exchange and high dose immunoglobulin in myasthenia gravis. Ann Neurology 41: 789–796. - PubMed
-
- Haas M., Mayr N., Zeitlhofer J., Goldammer A., Derfler K. (2002) Long-term treatment of myasthenia gravis with immunoadsorption. J Clin Apher 17: 847. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources